140 studies found for:    thalidomide myeloma | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide, cyclophosphamide, dexamethasone;   Drug: thalidomide, cyclophosphamide, dexamethasone;   Drug: bortezomib, cyclophosphamide, dexamethasone;   Drug: lenalidomide maintenance;   Drug: lenalidomide plus vorinostat maintenance
2 Unknown  Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: thalomid;   Drug: lenalidomide;   Drug: clarithromycin;   Drug: dexamethasone
3 Recruiting Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Thalidomide Celgene™
4 Recruiting Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: Auto-Allo Tandem SCT and maintenance therapy with Thalidomide/ DLI;   Procedure: auto-auto Tandem stem cell transplantation and maintenance therapy with Thalidomide
5 Unknown  Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine + Dexamethasone + Thalidomide
6 Not yet recruiting Efficacy Study Comparing VELCADE DEXAMETHASONE THALIDOMIDE Versus VELCADE CYCLOPHOSPHAMIDE DEXAMETHASONE as Induction Treatment in the Initial Management of Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Thalidomide®;   Drug: Cyclophosphamide;   Drug: Velcade®;   Drug: Dexaméthasone
7 Unknown  Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: thalidomide;   Drug: idarubicin
8 Unknown  Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: platelet aggregation test
9 Recruiting Velcade (Bortezomib) Consolidation After Transplant
Condition: Multiple Myeloma
Interventions: Drug: Thalidomide;   Drug: Bortezomib
10 Recruiting Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Velcade;   Drug: Thalidomide;   Drug: Dexamethasone;   Drug: Panobinostat
11 Recruiting Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
Condition: Myeloma
Interventions: Drug: Thalidomide;   Drug: Lenalidomide;   Behavioral: Questionnaires
12 Recruiting Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Conditions: Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
13 Unknown  Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib,Pirarubicin,Dexamethasone;   Drug: Thalidomide,Pirarubicin,Dexamethasone
14 Recruiting Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma
Condition: Multiple Myeloma
Intervention: Procedure: Single ASCT with Thalidomide maintenance
15 Unknown  TCD Followed by autoSCT for Newly Diagnosed MM Patients
Condition: Multiple Myeloma
Intervention: Drug: Thalidomide
16 Not yet recruiting Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
Conditions: Multiple Myeloma;   Neoplasms;   Plasma Cells;   Paraproteinemias;   Blood Protein Disorders;   Hematologic Diseases;   Therapeutic Uses
Intervention: Drug: Lenalidomide
17 Recruiting A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: Velcade;   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Prednisone;   Drug: Thalidomide;   Drug: Diphenhydramine;   Drug: Acetaminophen
18 Unknown  PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Velcade;   Drug: Thalidomide;   Drug: Adriamycin;   Drug: Dexamethasone
19 Unknown  Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
Condition: Multiple Myeloma
Intervention: Drug: Thalidomide, cyclophosphamide, dexamethasone, bortezomib
20 Recruiting Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)
Condition: Myeloma
Intervention: Drug: Velcade, Revlimid, Dexamethasone, Melphalan, Cisplatin, Thalidomide

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years